Message from the Regulators: Pharmacovigilance to Move Heavily into Risk-Benefit Assessment

Add bookmark

Message from the Regulators: Pharmacovigilance to Move Heavily into Risk-Benefit Assessment

Add bookmark
Pilar Carrero Director of Safety Medical Writing at Novo Nordisk, joins Andrea Charles from Pharma IQ, to discuss the impact social media has had on drug safety and risk managment and the dawn of a new era for pharmacovigilance. Carrero also shares her insights on optimising pharmacovigilance activities and complying with the Development Safety Update Report (DSUR).  [inlinead] 

Latest Webinars

Pharma IQ's Power List 2022: In conversation with pharma's top leaders

2022-10-18

02:00 PM - 03:00 PM BST

Join us to hear from the most influential people in pharma today, as voted for by you

A post-pandemic 3D view of the patient and supply journey

2022-06-01

04:30 PM - 05:30 PM CET

In this panel discussion with experts from 4G Clinical, THREAD Research and World Courier, learn how...

Discover how targeted radiotherapy induced toxicity can be identified with imaging

2022-04-28

01:00 PM - 02:00 PM EST

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the...

Recommended